STOCK TITAN
  1. Home
  2. ALBO

Albireo Pharma (ALBO) Stock Price, News & Analysis

ALBO NASDAQ

Company Description

Albireo Pharma (NASDAQ: ALBO) is classified in the pharmaceutical preparation manufacturing industry within the Manufacturing sector.

This page collects what Stock Titan holds for ALBO, including price data, latest news, SEC filings, insider trading activity, financial highlights, upcoming events, and short interest trends.

Stock Performance

Chart
$—
0.00%
0.00
Last updated:
-
Performance 1 year
$0.0
Market Cap
20.7M
Shares outstanding

Latest News

View All
+0.23%

FDA Grants June 15, 2023 PDUFA Date to Albireo for Bylvay® in Alagille Syndrome

fda approval
+92.16%

Ipsen to Acquire Albireo Accelerating Growth in Rare Disease With Treatments for Several Pediatric Liver Diseases

acquisition
-7.54%

Albireo Submits Bylvay® Alagille Syndrome Regulatory Filings to FDA and EMA

fda approval
-0.14%

Albireo Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

-2.82%

Albireo Appoints Paul Streck, M.D., as Chief Medical Officer & Craig Hopkinson, M.D., to Board of Directors

management
+3.03%

Reimbursed Access to Bylvay® (odevixibat) Approved in France for Patients with PFIC 1 & 2

Albireo Pharma has 10 recent news articles. Of the recent coverage, 4 articles coincided with positive price movement and 6 with negative movement. Key topics include fda approval, acquisition, management, conferences, earnings. View all ALBO news →

SEC Filings

View All

No SEC filings available for ALBO.

Financial Highlights

—
Revenue (latest FY)
—
Net Income (latest FY)
—
Diluted EPS (latest FY)
—
Operating Cash Flow
—
Net Profit Margin
—
Oper. Profit Margin

Upcoming Events

Short Interest History

Last 12 Months

Days to Cover History

Last 12 Months

ALBO Company Profile & Sector Positioning

Albireo Pharma (ALBO) operates in the Pharmaceutical Preparation Manufacturing industry within the broader Manufacturing sector and is listed on the NASDAQ.